PTC Therapeutics Signs Definitive Agreement to Acquire ST-920 Gene Therapy for $111M Upfront
PTCT sits 43% above its 52-week low of $48.955.
Summary
PTC Therapeutics signed a definitive agreement to acquire ST-920 from Sangamo for $111 million upfront plus up to $100 million in FDA approval milestones. Bankruptcy court approval hearing is scheduled for September 10, 2026.
Key Events · M&A and Partnerships · PTCT
-
Definitive Agreement Signed
PTC Therapeutics entered into an asset purchase agreement with Sangamo Therapeutics on August 25, 2026 to acquire ST-920, a one-time AAV gene therapy for Fabry disease.
-
Deal Terms Finalized
Upfront payment of $111 million plus up to $100 million in contingent milestones: $80 million upon accelerated FDA approval and $20 million upon full approval.
-
Bankruptcy Court Approval Hearing
Hearing before the U.S. Bankruptcy Court for the District of Delaware is scheduled for September 10, 2026 to consider approval of the acquisition.
-
Closing Deadline
Either party may terminate the agreement if closing has not occurred by October 15, 2026, subject to specified exceptions.
Analysis · PTCT · Life Sciences
PTC Therapeutics has formalized its acquisition of ST-920, a BLA-stage gene therapy for Fabry disease, by entering into a definitive asset purchase agreement with Sangamo Therapeutics. The deal structure is now concrete: $111 million upfront plus up to $100 million in milestone payments tied to FDA approval. A bankruptcy court hearing is set for September 10, 2026, with an outside closing date of October 15, 2026. This adds certainty to a transaction that was previously announced only as a winning auction bid, and the milestone structure aligns PTC's payments with regulatory success.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PTCT was trading at $70.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.8B. The 52-week trading range was $48.96 to $90.87. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.